Immune Escape in Prostate Cancer: Known and Predicted Mechanisms and Targets

Boris A Reva; Tatiana Omelchenko; Sujit S Nair; Ashutosh K Tewari

doi:10.1016/j.ucl.2020.10.004

Immune Escape in Prostate Cancer: Known and Predicted Mechanisms and Targets

Urol Clin North Am. 2020 Nov;47(4S):e9-e16. doi: 10.1016/j.ucl.2020.10.004. Epub 2020 Dec 9.

Authors

Boris A Reva¹, Tatiana Omelchenko², Sujit S Nair³, Ashutosh K Tewari³

Affiliations

¹ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: boris.reva@mssm.edu.
² Cell Biology Program, Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
³ The Department of Urology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1272, New York, NY 10029, USA.

PMID: 33446324
DOI: 10.1016/j.ucl.2020.10.004

Abstract

Complex immune evasion mechanisms and lack of biomarkers predicting responsiveness to immune checkpoint blockade therapies compromise immunotherapy's therapeutic efficacy for patients with prostate cancer. The authors review established and nominated immune evasion mechanisms in prostate cancer and discuss how the precise treatment strategies can be developed to improve efficacy of immunotherapy.

Keywords: IFN-γ signaling; Immune evasion; Immunotherapy; Prostate cancer.

Publication types

Review

MeSH terms

Humans
Immune Checkpoint Inhibitors / immunology*
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy
Interferon-gamma / genetics
Interferon-gamma / immunology*
Male
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / immunology*
Tumor Escape / drug effects
Tumor Escape / immunology*

Substances

Immune Checkpoint Inhibitors
Interferon-gamma